NK cells control breast cancer and related cancer stem cell hematological spread.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 28405511)

Published in Oncoimmunology on February 23, 2017

Authors

Rossana Tallerico1, Laura Conti2, Stefania Lanzardo2, Rosa Sottile3, Cinzia Garofalo1, Arnika K Wagner4, Maria H Johansson4, Costanza Maria Cristiani1, Klas Kärre4, Ennio Carbone3, Federica Cavallo2

Author Affiliations

1: Tumor Immunology and Immunopathology Laboratory, Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro , Catanzaro, Italy.
2: Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Turin , Turin, Italy.
3: Tumor Immunology and Immunopathology Laboratory, Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro, Catanzaro, Italy; Department of Microbiology, Cell and Tumor Biology (MTC), Karolinska Institutet, Stockholm, Sweden.
4: Department of Microbiology, Cell and Tumor Biology (MTC), Karolinska Institutet , Stockholm, Sweden.

Articles cited by this

Stem cells, cancer, and cancer stem cells. Nature (2001) 50.27

Efficient tumour formation by single human melanoma cells. Nature (2008) 16.35

NK cell recognition. Annu Rev Immunol (2005) 14.40

A severe combined immunodeficiency mutation in the mouse. Nature (1983) 13.99

Applying the principles of stem-cell biology to cancer. Nat Rev Cancer (2003) 8.95

Innate lymphoid cells--a proposal for uniform nomenclature. Nat Rev Immunol (2013) 7.94

Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature (1988) 6.38

The biology of cancer stem cells. Annu Rev Cell Dev Biol (2007) 6.23

Cancer stem cells: lessons from leukemia. Trends Cell Biol (2005) 3.90

Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol (2004) 3.41

NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest (2009) 2.08

Natural killer cell education and tolerance. Cell (2010) 2.02

DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med (2008) 2.00

Molecular definition of the identity and activation of natural killer cells. Nat Immunol (2012) 1.97

Heredity and cancer in man. Prog Med Genet (1973) 1.91

Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunol (2009) 1.76

NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J Immunol (2009) 1.46

Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. Int Immunol (2009) 1.37

Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res (2010) 1.37

Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules. J Immunol (2013) 1.11

A fluorescence NK assay using flow cytometry. J Immunol Methods (1986) 1.06

Targeting of surface alpha-enolase inhibits the invasiveness of pancreatic cancer cells. Oncotarget (2015) 0.99

The noninflammatory role of high mobility group box 1/Toll-like receptor 2 axis in the self-renewal of mammary cancer stem cells. FASEB J (2013) 0.99

Cancer risk: role of environment—response. Science (2015) 0.99

Metastatic consequences of immune escape from NK cell cytotoxicity by human breast cancer stem cells. Cancer Res (2014) 0.98

Natural killer cell tolerance persists despite significant reduction of self MHC class I on normal target cells in mice. PLoS One (2010) 0.96

Stem cells: their role in breast cancer development and resistance to treatment. Curr Pharm Biotechnol (2011) 0.95

Hansemann, Boveri, chromosomes and the gametogenesis-related theories of tumours. Cell Biol Int (2006) 0.91

NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype. J Immunol (2015) 0.91

Protective immunity against neu-positive carcinomas elicited by electroporation of plasmids encoding decreasing fragments of rat neu extracellular domain. Hum Gene Ther (2008) 0.90

IL-6, but not IFN-gamma, triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3 silencing. Leukemia (2009) 0.87

Attenuation of PI3K/Akt-mediated tumorigenic signals through PTEN activation by DNA vaccine-induced anti-ErbB2 antibodies. J Immunol (2010) 0.87

Th17 cells in multiple sclerosis express higher levels of JAK2, which increases their surface expression of IFN-γR2. J Immunol (2012) 0.86

Immunotargeting of Antigen xCT Attenuates Stem-like Cell Behavior and Metastatic Progression in Breast Cancer. Cancer Res (2015) 0.84

Multi-level model for the investigation of oncoantigen-driven vaccination effect. BMC Bioinformatics (2013) 0.83

Human Induced Pluripotent Stem Cells Are Targets for Allogeneic and Autologous Natural Killer (NK) Cells and Killing Is Partly Mediated by the Activating NK Receptor DNAM-1. PLoS One (2015) 0.82

Multiple roles of perforin in hampering ERBB-2 (Her-2/neu) carcinogenesis in transgenic male mice. J Immunol (2014) 0.81

Microenvironment, oncoantigens, and antitumor vaccination: lessons learned from BALB-neuT mice. Biomed Res Int (2014) 0.81

Targeting ferritin receptors for the selective delivery of imaging and therapeutic agents to breast cancer cells. Nanoscale (2015) 0.81

Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice. Oncoimmunology (2013) 0.81

Optical imaging detection of microscopic mammary cancer in ErbB-2 transgenic mice through the DA364 probe binding αv β3 integrins. Contrast Media Mol Imaging (2013) 0.80

A mathematical-biological joint effort to investigate the tumor-initiating ability of Cancer Stem Cells. PLoS One (2014) 0.79

L-Ferritin targets breast cancer stem cells and delivers therapeutic and imaging agents. Oncotarget (2016) 0.78

Mn-loaded apoferritin: a highly sensitive MRI imaging probe for the detection and characterization of hepatocarcinoma lesions in a transgenic mouse model. Contrast Media Mol Imaging (2012) 0.78